Skip to main content

Research Repository

Advanced Search

Professor Adrian Brunt's Outputs (45)

Comparison of CT-volumed supraclavicular fossa radiotherapy planning and conventional simulator-planned defined by bony landmarks for early breast cancer (2016)
Journal Article
Brunt, A. M., Lupton, S., Thorley, K., Pearce, L., & Handley, J. (2016). Comparison of CT-volumed supraclavicular fossa radiotherapy planning and conventional simulator-planned defined by bony landmarks for early breast cancer. Reports of Practical Oncology and Radiotherapy, 21(3), 219-224. https://doi.org/10.1016/j.rpor.2016.02.004

Aim
A comparison of techniques, CT planning of the supraclavicular fossa and field based simulation. We highlight CT planned SCF radiotherapy which would be useful for a centre introducing the technique.

Background
Development of radiotherapy te... Read More about Comparison of CT-volumed supraclavicular fossa radiotherapy planning and conventional simulator-planned defined by bony landmarks for early breast cancer.

Time for a randomised clinical trial evaluating breast conserving surgery compared to mastectomy in ipsilateral mutlifocal breast cancer (MFBC)? (2016)
Journal Article
Winters, Z., Horsnell, J., Schmid, P., Jones, J., Shaaban, A., Maxwell, A., Williams, N., Esserman, L., Jatoi, I., Brunt, A., & Management Group, M. T. (2016). Time for a randomised clinical trial evaluating breast conserving surgery compared to mastectomy in ipsilateral mutlifocal breast cancer (MFBC)?. Breast, 26, 149-150. https://doi.org/10.1016/j.breast.2015.12.011

2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial (2013)
Journal Article
MD, P. A. G., PhD, P. R. D. G., MD, P. M. J. P.-G., MD, E. D. A., MSci, M. P., MD, P. T. M. S., MD, P. C. J., MD, P. D. C., MD, H. A. W., PhD, D. H., MD, L. D. L., MA, E. M., PhD, P. M. D., MD, P. M. U., MD, L. G., MD, P. R. B., MD, P. C.-H. K., MD, A. V., MD, M. A., MD, A. M. B., …MD †, P. J. B. (2013). 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial. The Lancet, 382(9897), 1021-1028. https://doi.org/10.1016/S0140-6736%2813%2961094-6

Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial (2013)
Journal Article
RD Johnston, S., Kilburn, L. S., Ellis, P., Dodwell, D., Cameron, D., Hayward, L., Im, Y.-H., Braybrooke, J. P., Brunt, A. M., Cheung, K.-L., Jyothirmayi, R., Robinson, A., Wardley, A. M., Wheatley, D., Howell, A., Coombes, G., Sergenson, N., Sin, H.-J., Folkerd, E., Dowsett, M., …investigators, S. (2013). Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial. Lancet Oncology, 14(10), 989-998. https://doi.org/10.1016/S1470-2045%2813%2970322-X